Sirtuin Inhibitor

Schisanhenol (Standard) (Schizanhenol (Standard)) is the analytical standard of Schisanhenol (HY-N0859). This product is intended for research and analytical applications. Schisanhenol, a lignan, is an orally active antioxidant. Schisanhenol reduces AChE activity, increases SIRT1 and PGC-1α expression, and decreases phosphorylated Tau (Ser 396) levels. Schisanhenol increases SOD and glutathione peroxidase activity, decreases malondialdehyde (MDA) content, and inhibits UGT2B7 activitY. Schisanhenol attenuates ox-LDL-induced apoptosis, intracellular reactive oxygen species generation, and cytotoxicity in endothelial cells. Schisanhenol inhibits LDL oxidation, brain mitochondrial and membrane peroxidative damage, and brain mitochondrial swelling and disintegration. Schisanhenol can be used for the research of Alzheimer’s disease, atherosclerosis, brain ischemia, and age-related brain deterioration.

SIRT5 inhibitor 8 (compound 10) is a competitive inhibitor (IC₅₀: 5.38 μM) of sirtuin SIRT5 with anticancer potential.

Sirt2-IN-7 (compound 22) is a selective inhibitor of SIRT2. Sirt2-IN-7 inhibits SIRT2 with an IC₅₀ value and a K_i value of 178.2 nM and 154.3 nM, respectively. Sirt2-IN-7 can be used for the research of cancer.

SIRT5 Inhibitor 6 is a potent, substrate-competitive and selective SIRT5 inhibitor with an IC₅₀ of 3.0 μM. SIRT5 Inhibitor6 has a therapeutic potential against septic AKI in vivo.

CypD-IN-5 (compound C-9) is a potent cyclophilin D (CypD) inhibitor. CypD-IN-5 can be used in the study of Alzheimer's disease.

Nicotinamide (GMP) (Niacinamide (GMP)) is the GMP level of Nicotinamide (HY-B0150). GMP guidelines are used to produce Nicotinamide (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC₅₀: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD₊, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.

SIRT2-IN-12 (Compound 3) is a SIRT2 inhibitor with a IC₅₀ value of 50 μM.

SIRT5 inhibitor 9 (compound 14) is a competitive inhibitor (IC₅₀: 4.07 μM) of sirtuin SIRT5 with anticancer potential.

Sirt7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sirt7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mz325 is a dual inhibitor of HDAC and Sirt2, with the IC₅₀ of 9.7 μM to Sirt2, that play an important role in pathogenesis of cancer and neurodegeneration.

SIRT-IN-5 is a SIRT3 inhibitor, with an IC₅₀ value of 2.88 μM. SIRT-IN-5 can promote the differentiation of multiple myeloma cells, along with an increase in the expression of the differentiation antigen CD49e and human immunoglobulin light chains λ and κ.

HSP70/SIRT2-IN-2 (Compounds 1a) is a dual inhibitor for SIRT2 and HSP70, with IC₅₀ of 45.1±5.0 μM for SIRT2. HSP70/SIRT2-IN-2 has antitumor activity.

Sirt1/2-IN-4 (compound PS3) is a triple inhibitor of SIRT1/2/3 with IC₅₀s of 1.2 μM (SIRT1), 1.9 μM (SIRT2), and 18.6 μM (SIRT3), respsectivley. Sirt1/2-IN-4 completely blocks p53 deacetylation, with potential anti-cancer activity.

Sirt5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sirt5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SIRT-IN-4 is an inhibitor of the NAD+-dependent lysine deacetylase Sirtuin2 (Sirt2) (IC₅₀=0.35 μM). SIRT-IN-4 is a potent Sirt2 deacetylase inhibitor that reduces cell survival and inhibits the migration of prostate cancer cells. SIRT-IN-4 can be used to study Sirt2 in cell cycle regulation, gene expression regulation, etc.

ZINC08792355 is a SIRT1 inhibitor and can be used for study of ageing, diabetes, and cancer..

NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity.

Sirt6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sirt6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Aristoforin, a hypericin derivative, inhibits the activities of SIRT1 and SIRT2. Aristoforin induces G1 phase cell cycle arrest, scavenges hydroxyl free radicals, and exhibits protective activity against Fe²⁺-induced DNA breakage. Aristoforin can be used in studies related to breast cancer and colon adenocarcinoma.

SIRT2-IN-13 (compound 7c) is an inhibitor of SIRT2 and induces apoptosis. SIRT2-IN-13 selectively inhibits colon cancer and leukemia cells and arrests the cell cycle in the G2 phase.